1/5Vitro Biopharma, Inc.: Filing-delay notice, quarterly report filed within extension (NT 10-Q)

Market data

n/a: no ticker symbol on the filing.

Insider trading around this filing

90 days before the flag: no open-market insider sales or purchases reported.
30 days after: none reported.

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-06-16 to 2026-10-14. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"Vitro Biopharma Inc. (the "Company") has determined that it is unable to file its Quarterly Report on Form 10-Q for the quarter ended July 31, 2026 by the original due date for such filing, without unreasonable effort or expense because it requires additional time to complete its financial statements. The Company expects that it will file the Form 10-Q no later than September 18, 2026."

Quoted from the filing. Source

What this means

The company filed Form NT 10-Q, telling the SEC it could not file its quarterly report on time, and then filed the report within the 5-day extension. The SEC treats a report filed within the extension as timely, so this is the mildest kind of flag, but the notice itself is a warning sign that investors often react to: something, often the audit or the accounting, took longer than planned.

Status: filed within extension (report filed 2026-09-18) · the SEC treats a report filed within the extension as timely

Why this score: report filed within the extension on 2026-09-18